Quanterix Corporation, a company advancing healthcare by accelerating biomarker discoveries from research to diagnostics, announced several leadership and governance updates to support its next phase of growth. The company has appointed two highly experienced life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Hampton previously served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. Dr. Sachs is the former Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific.
Health Technology Insights: enGene Reports 62% Complete Response for Detalimogene
In addition to these new appointments, Bill Donnelly, who had served as non-Executive Chair of the Board, has been promoted to Executive Chair. Jeffrey Elliott, a current Board member, has been named Lead Independent Director, a newly created role. As Executive Chair, Mr. Donnelly will collaborate closely with the company’s management team and provide guidance on strategic and operational priorities. This leadership structure allows Chief Executive Officer Masoud Toloue to continue focusing on key initiatives, including expanding Quanterix’s blood- and tissue-based biomarker menu, launching LucentAD Complete™ for Alzheimer’s diagnostics, and accelerating growth synergies from the Akoya acquisition.
Health Technology Insights: ModelOp Certified by CHAI for Trusted AI in Healthcare
At the same time, Paul Meister and David Walt, Ph.D., have stepped down from the Board after many years of service. With these changes, Quanterix’s Board now consists of nine members, seven of whom are independent.
Bill Donnelly, Executive Chair, welcomed the new Board members, stating that their combined expertise in diagnostics, life sciences, and product innovation will provide valuable perspectives. He emphasized that as the company moves beyond integration efforts and focuses on growth, their experience in scientific innovation and market strategy will be crucial. Donnelly also expressed gratitude to Paul Meister and David Walt for their significant contributions. He highlighted Dr. Walt’s pioneering work in precision medicine and Paul Meister’s insights as a life sciences investor, noting their roles in supporting the company’s growth and strategic direction.
CEO Masoud Toloue commented that he is excited to work with Garret Hampton and Alan Sachs, whose technical knowledge and business leadership will strengthen the Board. He added that Bill Donnelly’s expanded role will improve operational alignment and help accelerate the company’s growth initiatives. Together, these leadership changes position Quanterix to continue its role as a leader in tools and diagnostics while advancing its mission to improve patient health outcomes globally.
Bill Donnelly further stated that he looks forward to collaborating with CEO Toloue and the leadership team to advance strategic priorities. He noted that with the Akoya Biosciences acquisition completed and integration efforts progressing, Quanterix is entering a new era and is well-positioned to deliver meaningful value to shareholders, patients, and partners in the years ahead.
Health Technology Insights: PREFcards Secures U.S. Patent for Innovative Surgical Preference Card Optimization
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
